Physician

Norman B Gaylis, M.D.

According to 2025 Medicare claims, Norman Gaylis, M.D. (NPI: 1255440384) practices rheumatology in the Miami-Miami Beach-Kendall, FL market, with the plurality of this provider's patient population coming from Miami-Dade, FL. This provider's primary affiliated billing organization is NORMAN B. GAYLIS M.D. PA (NPI: 1003055203; TIN: 650901240) and primary practice location at 33180-1264. Gaylis is affiliated with the American Choice Healthcare, LLC (ACO ID: D0086), participating under the REACH model.

Gaylis' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 947 traditional Medicare patients, billed 385,140 HCPCS/CPT codes, and received $4,126,938 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,500 prescription claims across 647 beneficiaries totaling $2,688,497 in drug costs, led by Remicade (Infliximab). DME data shows 24 claims. Open Payments data shows 53 records totaling $291,220. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,584,361 to $4,126,938. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,228,262 and ending at $2,688,497. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $706 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	699	65,447	$1,584,361
2016	823	98,440	$2,477,382
2017	763	145,030	$2,763,526
2018	777	94,241	$2,569,471
2019	809	111,750	$2,735,602
2020	719	157,775	$3,021,782
2021	848	236,964	$4,047,056
2022	773	276,985	$3,642,441
2023	929	256,556	$3,548,054
2024	947	385,140	$4,126,938

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	718	3,342	$1,228,262
2016	731	2,759	$1,547,646
2017	594	2,050	$1,711,336
2018	539	1,948	$2,958,731
2019	540	2,216	$3,067,416
2020	415	1,927	$1,670,298
2021	442	1,735	$2,014,323
2022	457	1,860	$2,864,649
2023	515	1,870	$1,899,127
2024	647	2,500	$2,688,497

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	12	$224
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	13	$187
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	11	11	$8,099
2024	24	24	$16,172

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	576	1,165	$101
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	339	494	$68
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	280	1,397	$55
77080	Dxa bone density measurement of hip, pelvis, spine	269	271	$40
J0897	Injection, denosumab, 1 mg	324	30,482	$20

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Remicade	Infliximab	52	1,576	$306,538
Ruxience	Rituximab-Pvvr	23	630	$294,070
Enbrel Sureclick	Etanercept	31	868	$242,670
Evenity (2 Syringes)	Romosozumab-Aqqg	98	2,922	$239,173
Prolia	Denosumab	132	23,760	$227,331

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L0651	Lumbar-sacral orthosis, sagittal-coronal control, rigid shell(s)/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, anterior extends from symphysis pubis to xyphoid, produces intracavitary pressure to reduce load on the intervertebral discs, overall strength is provided by overlapping rigid material and stabilizing closures, includes straps, closures, may include soft interface, pendulous abdomen design, prefabricated, off-the-shelf	N	24	24	$16,172

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	19	$674	IntrinsiQ Specialty Solutions, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	34	$290,546	ABBVIE INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Norman B. Gaylis, M.D.?

Tedicare shows public-source Medicare data for Norman B. Gaylis, M.D. (NPI 1255440384), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Norman B. Gaylis, M.D. have ACO affiliation data?

Norman B. Gaylis, M.D. is shown with ACO affiliation data for American Choice Healthcare, LLC (REACH, ACO ID D0086).

What billing organization is linked to Norman B. Gaylis, M.D.?

Norman B. Gaylis, M.D. is linked to NORMAN B. GAYLIS M.D. PA (billing NPI 1003055203) in the available physician profile data.

Does Norman B. Gaylis, M.D. have Open Payments data?

Norman B. Gaylis, M.D. has 53 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.